TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00958204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light treatment
Description: Light therapy: from a 10,000 lux fluorescent white light box, for 30 minutes per day upon waking in the morning, for 8 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Light treatment
Description: Light therapy: from a 10,000 lux fluorescent white light box, for 30 minutes per day upon waking in the morning, for 8 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative ion therapy
Description: Negative ion therapy: from a negative ion generator with an output of 200 trillion ions per second per cubic centimeter, for 30 minutes per day upon waking in the morning, for 8 weeks

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Negative ion therapy
Description: Negative ion therapy: from a negative ion generator with an output of 200 trillion ions per second per cubic centimeter, for 30 minutes per day upon waking in the morning, for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Pill: one oral tablet each day, for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Pill: one oral tablet each day, for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine: 20 mg oral tablet each day, for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine: 20 mg oral tablet each day, for 8 weeks
Study: NCT01275482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse friction massage (TFM)
Description: The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue. During the massage, we can caused isolated contractions from the fiber muscles containing the latent trigger points.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse friction massage (TFM)
Description: The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse friction massage (TFM)
Description: The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue.
Study: NCT03759665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IB1001
Description: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
Study: NCT02599961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX007
Description: UX007 is a liquid intended for oral (PO) administration.
Study: NCT03440827

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focus Group
Description: First (phase 1), collect experiences, perceptions, difficulties, needs and expectations of patients with slow-flow malformations (for the age group of 11 to 15 years-old), carried out with 3 categories of participants and then (phase 2) development and validation of the specific scale of life's quality of slow-flow vascular malformation in children aged 11 to 15 years-old.
Study: NCT02997995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune-attractant
Description: The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).
Study: NCT01192802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole
Description: 1 tablet of 400 mg of albendazole per day for three consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole
Description: single 1 tablet of 400 mg of albendazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole
Description: 1 tablet of 400 mg of albendazole per day for two consecutive days
Study: NCT03963271

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG-Imaging
Description: A body surface potential mapping and a cardiac + low dose CT-scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG-Imaging
Description: A body surface potential mapping and a cardiac + low dose CT-scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG-Imaging
Description: A body surface potential mapping and a cardiac + low dose CT-scan.
Study: NCT03665025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate implant using mixed allograft and xenograft
Description: immediate implant using mixed allograft and xenograft in anterior area to fill jumping area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate implant using mixed allograft and xenograft
Description: immediate implant using mixed allograft and xenograft in anterior area to fill jumping area
Study: NCT01681355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula
Description: Standard cow's milk based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition
Study: NCT00943072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye 2.0mg
Description: Monthly intravitreal injection out to the Week 24 Primary endpoint

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Monthly sham intravitreal injection out to Week 24 Primary Endpoint
Study: NCT02933450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patiromer 25.2 g
Description: Single dose of Patiromer 25.2 g
Study: NCT01505764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anamorelin HCl
Description: 100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.
Study: NCT03774056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-1119
Description: oral
Study: NCT04475042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10mg od

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10mg od

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01039129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Cholecystectomy
Description: An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Appendectomy
Description: An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Peritoneoscopy
Description: A diagnostic peritoneoscopy with or without biopsy for any indication
Study: NCT02603666

Intervention type: DEVICE
Group type: OTHER
Intervention: Fibroscan
Description: Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.
Study: NCT00522236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008
Description: A single 0.5mL dose of Novartis adjuvanted subunit influenza vaccine, Fluad contained 45μg of viral hemagglutinin, composed of 15μg of the three influenza antigens:~* A(H1N1) strain: IVR-145 (Solomon Island/3/2006 - like strain)~* A(H3N2) strain: NYMC X-161B (A/Wisconsin/67/2005-like strain)~* B strain: (B/Malaysia/2506/2004-like strain) in accordance with the recommendations of the World Health Organization, the EU and the national Regulatory Agencies for the 2007/2008 season.~The vaccine is a milky liquid, and was packaged in ready to use, single dose syringes.~A single dose of FLUAD vaccine was administered intramuscularly, preferably in the deltoid muscle of the non dominant arm.
Study: NCT00336830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MD-endorsed Cardiac Rehabilitation referral
Description: Note to patient with general description of the Cardiac Rehabilitation program with signature and strong recommendation from attending physician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cardiac Rehabilitation referral
Description: Note to patient with general description of the Cardiac Rehabilitation program without signature or recommendation from attending physician.
Study: NCT03310489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitalized cognitive-behavioral intervention for anxiety
Description: An internet-based CBT, including telephone coaching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation about anxiety
Description: Psychoeducative material about anxiety in internet
Study: NCT02052076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal pattern

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Meal pattern
Study: NCT02223702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 500 mg, 3 times per day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 500 mg, 3 times per day, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg, once in a day for 7 days.
Study: NCT01754402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.
Study: NCT02997995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (lymphocyte activation) will be administrated at a dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: After three weeks (+/- 3 days) of immune-attractants, a tumor biopsy will be done. Patients who present \>10% CD8+ cells in the tumor after 3 weeks will receive the Durvalumab
Study: NCT01754402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
Study: NCT03896256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine infusion
Description: Ketamine will be used in subanesthetic doses for patients with refractory chronic migraine to see if it improves pain after a 5-day continuous infusion.
Study: NCT00822926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Subcutaneous injection of saline into scar tissue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Subcutaneous injection of saline into scar tissue
Study: NCT01204008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conservative discectomy
Description: a smaller incision with removal of the disc fragment with little invasion of the disc

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aggressive discectomy
Description: a large open incision with aggressive removal of the disc fragments and curettage of the disc space
Study: NCT04206280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of a pedometer following surgery
Description: Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
Study: NCT04502940

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometric analysis
Description: Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine lymphocyte subgroups

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometric analysis
Description: Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine lymphocyte subgroups

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometric analysis
Description: Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine lymphocyte subgroups

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometric analysis
Description: Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine lymphocyte subgroups
Study: NCT04142983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adacel
Description: 0.5 mL, Intramuscular
Study: NCT00852293

Intervention type: OTHER
Intervention: A blood test
Description: A blood test of about 5ml of blood will be taken to determine Chitinase 3 like-1 protein levels.
Study: NCT03445078

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: selenium supplementation
Description: administration of selenium-rich corn powder 20g/d offering selenium 100μg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: selenium supplementation
Description: administration of selenium-rich corn powder 20g/d offering selenium 100μg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ordinary corn powder
Description: ordinary corn powder,20g/d(selenium contain \<0.5ug/20g).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ordinary corn powder
Description: ordinary corn powder,20g/d(selenium contain \<0.5ug/20g).
Study: NCT00138736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannan Binding Lectin (MBL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannan Binding Lectin
Description: MBL dose at a twice weekly dose interval (3 or 4 days):~0.2 mg/kg, for a 3-day interval; 0.3 mg/kg, for a 4-day interval
Study: NCT01531114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: Patients will be randomized to this arm to receive loading dose of ticagrelor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: Patients will be randomized to this arm to receive loading dose of prasugrel
Study: NCT05628714

Intervention type: OTHER
Intervention: Patient decision aid for patients with superficial basal cell carcinoma
Description: An online WebApp
Study: NCT03723629

Intervention type: OTHER
Intervention: No intercention
Description: No intercention
Study: NCT03187600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucosa/submucosa Pharyngeal Flap
Description: Included in study arm description

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Pharyngeal Flap
Description: Included in study arm description
Study: NCT05315466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Description: Analgesics, anti-inflammatories, muscle relaxants, physical therapy, Global Postural Rehabilitation, magnetic therapy, laser therapy, transcutaneous electrical nervous stimulation (TENS), massage, cognitive-behavioral therapy and all those procedures that can bring benefit to back and leg pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment for spinal stenosis
Description: Decompression of nerve structures by laminotomy or laminectomy and posterior lumbar fusion if stabilization of the column is required.
Study: NCT04188184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
Study: NCT02491294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School
Description: students receive Cooking With Kids (CWK) - Colorado cooking \& tasting lessons, SPARK active recess, and Cafeteria Connections
Study: NCT01788358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
Study: NCT02491294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School
Description: students receive Cooking With Kids (CWK) - Colorado cooking \& tasting lessons, SPARK active recess, and Cafeteria Connections

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School
Description: students receive Cooking With Kids (CWK) - Colorado cooking \& tasting lessons, SPARK active recess, and Cafeteria Connections
Study: NCT03546868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FSPG
Description: Patients will receive 200 MBq of \[18F\]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FSPG
Description: Patients will receive 200 MBq of \[18F\]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease
Study: NCT02429180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~* Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~* Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~* Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~* Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression.
Study: NCT04085900

Intervention type: BIOLOGICAL
Intervention: Blood and saliva
Description: Collect blood and saliva samples from participants

Intervention type: DIAGNOSTIC_TEST
Intervention: P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA
Description: Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fiberoptic endoscopy and biopsy
Description: Screening participants will refer to fiberoptic endoscopy and biospy
Study: NCT02727439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Exhausting Exercise (AE)
Description: A single progressive rowing training to maximal exhaustion (AE).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Exhausting Exercise (AE)
Description: A single progressive rowing training to maximal exhaustion (AE).